Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents
Gilardini, Luisa, McTernan, P. G. (Philip G.), Girola, Andrea, da Silva, Nancy F., Alberti, Luisella, Kumar, Sudhesh and Invitti, Cecilia. (2006) Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents. Atherosclerosis, Volume 189 (Number 2). pp. 401-407. ISSN 0021-9150Full text not available from this repository.
Official URL: http://dx.doi.org/10.1016/j.atherosclerosis.2005.1...
The aim of this study was to compare the use of several biomarkers to identify obese children and adolescents with increased metabolic risk. One hundred sixty-two Caucasian obese children and adolescents (41% males, 9-18 years old) referred to the Istituto Auxologico Italiano between 2003 and 2004 underwent an oral glucose tolerance test. Circulating levels of adiponectin (AD), plasminogen activator inhibitor I (PAI-1), interleukin 18 (IL-18), C-reactive protein (CRP), fibrinogen, uric acid, lipids and insulin were measured. Twenty five percent of obese children had the MS defined using World Health Organization-derived child specific criteria. MS subjects had significantly lower AD (p < 0.01) and higher log-PAI-I (p < 0.001), uric acid (p < 0.0001), and IL-18 (p < 0.001). Subjects with AD levels <= median value had a significantly increased risk of having the MS (p < 0.0001), as did subjects with uric acid and PAI-1 levels greater than the median. There was no increased risk with elevated IL-18, CRP, or fibrinogen. Hypoadiponectmemia was independently associated with the MS risk (p < 0.0001). In conclusion in obese children and adolescents AD is the best predictor of MS and thus of higher cardiovascular disease risk. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
|Item Type:||Journal Article|
|Subjects:||R Medicine > RC Internal medicine|
|Divisions:||Faculty of Medicine > Warwick Medical School|
|Journal or Publication Title:||Atherosclerosis|
|Publisher:||Elsevier Ireland Ltd.|
|Number of Pages:||7|
|Page Range:||pp. 401-407|
|Access rights to Published version:||Restricted or Subscription Access|
Actions (login required)